Dogwood Therapeutics, Inc. DWTX
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is an oncology drug developer. Its lead program, Halneuron® (HAL-CINP-203), is in Phase 2 for Chemotherapy-induced neuropathic pain (CINP). Its next catalyst on record is Halneuron® HAL-CINP-203: Top-line data from Phase 2b trial (November 2026).
Upcoming catalysts
- November 2026Halneuron® HAL-CINP-203 — Top-line data from Phase 2b trial
The investment comes as Dogwood continues to advance its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial toward topline data readout in November 2026.
Next further out: Halneuron® HAL-CINP-203 Part 2 OLE — Final data from open-label extension (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Halneuron® (HAL-CINP-203) | Chemotherapy-induced neuropathic pain (CINP) | small molecule | Phase 2 |
| Halneuron® OLE (HAL-CINP-203 Part 2) | Chemotherapy-induced neuropathic pain (CINP) | small molecule | Phase 2 |
| SP16 IV | Chemotherapy-induced peripheral neuropathy (CIPN) | protein/peptide | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.